THE EMERGENT SCIENCE OF HDL AND ITS METABOLISM: Mechanistic Understanding of CETP Antagonism and Beyond

Title:

THE EMERGENT SCIENCE OF HDL AND ITS METABOLISM: Mechanistic Understanding of CETP Antagonism and Beyond

Topic: Cardiology
Relevant Terms: Anti-atherogenic Effects, CETP Antagonism, Cholesterol Biosynthesis, Cholesterol Efflux, Complex Dyslipidemia, CVD Risk, HDL-C
Primary Audience: Cardiologists; Endocrinologists; Lipidologists; Pharmacists; Registered Nurses; Registered Dietitians; and other healthcare professionals involved in managing CVD risk in patients with complex dyslipidemia
Launch Date: 01-Oct-12
Credits: AMA PRA Category 1 Credit
1 ACPE contact hour
1 ANCC contact hour
1 CDR continuing professional education unit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: The Emergent Science of HDL and its Metabolism

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Explain current research defining the mechanisms underlying cholesteryl ester transfer protein (CETP) inhibition and its impact on HDL metabolism;
  2. Describe the mechanisms involved in the production, metabolism, and functionality of HDL including how they relate to atherogenesis;
  3. Discuss recent evidence regarding the utility of HDL as a target for CVD risk modification including the clinical implications for patient management;
  4. Compare the relative effectiveness of existing treatments and emergent approaches to raise HDL and reduce CVD risk.
  5. For Registered Nurses and Nurse Practitioners Only: Provide appropriate care and counsel for patients and their families

    Faculty

    Peter P. Toth, MD, PhD, FNLA*
    Director of Preventive Cardiology
    Sterling Rock Falls Clinic, Ltd.
    Chief of Medicine, CGH Medical Center
    Sterling, Illinois
    Clinical Professor
    University of Illinois School of Medicine
    Peoria, IL
    H. Bryan Brewer, Jr., MD, FNLA*
    Director, Washington Cardiovascular Associates
    Senior Research Consultant
    Lipoprotein and Atherosclerosis Research
    MedStar Research Institute
    Washington Hospital Center
    Washington, DC
    Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA
    Professor of Medicine
    Mount Sinai School of Medicine
    Director
    Cardiometabolic Disorders
    Mount Sinai Heart
    New York, NY
    Criteria for Success
    Statements of credit will be awarded based on the participant's attendance at each session and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme. If you have questions about this CME/CE activity, please contact the NLA at cme@lipid.org. Please claim credit by September 30, 2013.

    COMMERCIAL SUPPORT –
    This activity is supported by an educational grant from Genentech, USA.
     
    CREDIT DESIGNATION
     
    FEE There is no fee associated with this activity.
     
    CME credit provided by the National Lipid Association
     
    PHYSICIANS – The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education. The National Lipid Association designates this enduring internet activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
     
    PHYSICIAN ASSISTANTS – NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.
     
     
    CE Credit provided by Postgraduate Institute for Medicine
     
     
    PHARMACISTS – Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
    Universal Activity Number – 0809-9999-12-358-H01-P (Knowledge)
    Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hours (0.01 CEUs) of the Accreditation Council for Pharmacy Education.
     
    NURSING – This educational activity for 1 contact hours is provided by Postgraduate Institute for Medicine.
    Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
     
    DIETITIANS – This program has been approved by the Commission on Dietetic Registration for ­­1.0 CPEUs.
     
    FACULTY/PLANNER FINANCIAL DISCLOSURES
    Name
    Relationship
    Company
    Brewer, H. Bryan, Jr.
    Consultant
    Cerenus; CSL; Lilly; Medicines Company, Merck & Co., Inc.; Pfizer, Roche/Genentech
    Rosenson, Robert S.
    Advisory Board
    Abbott Laboratories, Inc.; Amgen; Genentech; LipoScience, Inc.; Sanofi-aventis; Grain Food Foundation; AstraZeneca
    Contracted Research
    Amgen; Genentech; Roche Pharmaceuticals
    Ownership Interest
    LipoScience, Inc.
    Toth, Peter P.
    Consultant
    Abbott Laboratories, Inc.; AstraZeneca; Kowa Pharmaceuticals America Inc.; Amgen; Amylin Pharmaceuticals; Merck & Co., Inc.
    Speakers Bureau
    Abbott Laboratories, Inc.; AstraZeneca; Boehringer Ingelheim; Merck & Co., Inc.; Kowa Pharmaceuticals America, Inc.; GlaxoSmithKline; Amylin Pharmaceuticals
     
    NLA
    N/A
    Nothing to disclose
    PIM
    N/A
    PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
     
    DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT – This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    DISCLOSURE DECLARATION – It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.
     
    DISCLAIMER – This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader's misunderstanding of content.

    System Requirements
    To view this educational activity you will need one of the following web browsers: Google Chrome for Windows, Mac, or Linux; Internet Explorer 7.0+ for Windows; Mozilla 1.4+ for Windows, Mac, or Linux; Firefox 3.5+ for Windows, Mac, or Linux; or Safari 4.0+ for Mac.